questionText: To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of the proposals in the National Institute for Health and Care Excellence's final draft guidance, issued on 14 August 2025, to not recommend using cerliponase alfa, also called Brineura, for the treatment of children newly diagnosed with neuronal ceroid lipofuscinosis type 2, also called CLN2.
answerText: The National Institute of Health and Care Excellence (NICE) makes its decisions independently of the Government and in line with its carefully developed methods and processes. It would not therefore be appropriate for the Department to comment on or inter...
heading: Cerliponase Alfa: Batten Disease